葛兰素史克Glaxosmithkline（GSK）2025年年度报告「LSE」（英文版）（331页）.pdf

1、 Inside this reportStrategic reportOur purpose,strategy and culture 1Business model22025 performance and keyperformanceindicators4Key approvals in 20256Chairs statement8CEOs statement10Our external environment11Research and development14Commercial operations35Responsible business47Our culture and pe

2、ople59Risk management and disclosurestatements62Group financial review79Corporate governanceThe Board and Executive Committee109Chairs governance statement115Corporate governance architecture118Board activities121Board committee reports129Remuneration report140Directors report169Financial statements

3、Directors statement of responsibilities172Independent auditors report174Financial statements186Notes to the financial statements190Financial statements of GSK plc preparedunder UK GAAP274Investor informationFinancial record280Product development pipeline284Principal risks and uncertainties289Share c

4、apital and control305Dividends307Financial calendar 2026308Annual General Meeting 2026308Tax information for shareholders309Shareholder services and contacts USlawand regulation311Group companies316Glossary of terms324 How to navigate this reportPage reference for more information withinthis Annual

5、ReportSee for more information Our supplementsOur Responsible Business Report is available on Cover image:Multiple myeloma cancer cells among red blood cells and antibodies.We focus our oncology innovation on where we can make the most meaningful difference.This includes in multiple myeloma,a blood

6、cancer where new therapies are needed asit commonly becomes resistant toavailable treatments.In 2025,wereceived major approvals for Blenrep,including in the US,Europeand Japan,for patients withmultiple myeloma.Cautionary statementSee the inside back cover of this document for the cautionary statemen